Clinical Trials in Organ Transplantation (Ctot)

The summary for the Clinical Trials in Organ Transplantation (Ctot) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Clinical Trials in Organ Transplantation (Ctot): The Division of Allergy, Immunology, and Transplantation (DAIT) of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) invites applications from consortia of 2 or more institutions to participate in a clinical studies program of immune-mediated pathologic processes in organ transplantation. The purpose of this program is to support a cooperative, multi-site consortium for interventional or observational clinical studies, accompanied by mechanistic studies, to enhance our understanding of and ultimately reduce the immune-mediated morbidity and mortality of organ transplantation. These studies will be carried out in pediatric and adult candidates for and recipients of organ transplants as multi-center clinical trials that will (1) evaluate new therapeutic regimens to overcome immunologic barriers to graft acceptance and/or long-term graft and patient survival, (2) evaluate approaches to the treatment or prevention of immune-mediated complications of transplantation; (3) investigate the underlying mechanisms of action of the pathologic processes, agents or regimens under study; (4) develop diagnostic tests for and/or surrogate biomarkers that will facilitate routine surveillance, early diagnosis and ongoing monitoring of those processes that contribute to post-transplant morbidity and mortality. Studies of hematopoietic stem cell transplantation (HSCT) are excluded, unless HSCT is a component of a study of organ transplantation. Studies of islet transplantation for treatment of type I diabetes are also excluded.